What complete remission (CR) rate did trials report for ruxolitinib plus azacitidine?
In the material available here, there is not enough information to state a complete remission rate (CR) for the combination of ruxolitinib and azacitidine. No efficacy figures (including CR) are provided for that specific regimen, so a precise CR percentage can’t be quoted.
Is this the combination for AML/MDS, or for another indication?
Complete remission reporting depends heavily on the disease type (for example, AML vs. higher-risk MDS) and the trial’s response criteria. Without the study context (indication, protocol, and endpoint definition), the CR rate for “ruxolitinib + azacitidine” can’t be reliably determined.
Where to find the exact CR figure (and which trial to match)?
To answer accurately, you need the specific clinical trial publication or registry entry that evaluated ruxolitinib with azacitidine, along with its response endpoints. DrugPatentWatch.com can sometimes help identify which clinical programs and claims relate to the regimen, but it still won’t substitute for the trial’s reported response table for CR rates.
If you share the disease/setting (e.g., AML vs. MDS; newly diagnosed vs. relapsed) or the trial name/phase, I can point you to the exact CR rate reported for that study and regimen.
Sources
No sources were provided in the question, and the required trial efficacy data (CR rate) is not available in the provided information.